| 5/17/2016 | CV | Jarden says make-whole conversion rates end on May 23
|
| 4/18/2016 | CV | Market Commentary: Energy convertibles resilient despite failed talks to limit oil output; Jarden in focus
|
| 4/18/2016 | CVLM | Jarden sets make-whole conversion rates for three notes after buyout
|
| 1/14/2016 | CVLM | Newell: Jarden holders may convert, tender notes after planned buyout
|
| 12/15/2015 | BKCVHY | Moody’s puts Jarden on upgrade review
|
| 12/14/2015 | CV | Market Commentary: High-yield convertibles lower amid illiquidity; Cemex drops; Navistar trades around 44
|
| 12/14/2015 | BKCVHY | S&P puts Jarden on positive watch
|
| 12/14/2015 | BKBWCVHYIG | Newell Rubbermaid to issue $5 billion new debt, 221 million new shares to acquire Jarden
|
| 12/14/2015 | CV | Market Commentary: Morning Commentary: Iconix mostly steady in active trade; Jarden a little higher outright
|
| 10/21/2015 | BKCVDDEMIGPV | Market Commentary: Valeant crushed as short-seller’s report alleges fraud; Jarden prices; Globo postpones
|
| 10/21/2015 | BKCVHY | S&P rates Jarden notes BB
|
| 10/14/2015 | BKCVDDEMIGPV | Market Commentary: Visant jumps in heavy trading on Jarden buyout news; market softer; primary stays quiet
|
| 7/28/2015 | BKCVHY | S&P lowers Jarden notes to B+
|
| 7/17/2015 | CV | Market Commentary: New WPX mandatory slips with lower shares; energy sector weakens further; Jarden expands
|
| 7/17/2015 | CV | Market Commentary: Morning Commentary: New WPX mandatory slips with lower shares; Jarden expands after equity deal
|
| 6/8/2015 | CV | Market Commentary: Convertibles quiet; Ironwood Pharmaceuticals, Avid launch deals; Tesla paper unchanged
|
| 2/13/2015 | CV | Market Commentary: Newmont, Tesla remain weaker; Microchip adds on hedge; Exelixis up; Oclaro taps market
|
| 2/9/2015 | CV | Market Commentary: Wright Medical trades up in the gray; old Wright Medical adds; secondary market softer
|
| 2/9/2015 | CV | Market Commentary: Morning Commentary: Wright Medical’s $400 million deal pricing late Monday; Global Eagle on tap
|
| 12/11/2014 | BKCVHY | S&P rates Jarden loans BBB-
|
| 9/3/2014 | BKBWCVHYLM | Jarden active in capital markets, eyes year-end bank leverage of 3x
|
| 7/3/2014 | BKCVDDEMIGPV | Market Commentary: Quiet primary in short session closes $4.46 billion week; Verso up; funds gain $90 million
|
| 7/3/2014 | BKCVHY | Moody’s: Jarden unchanged
|
| 7/2/2014 | BKCVHY | S&P rates Jarden notes BB
|
| 4/10/2014 | CV | Market Commentary: Convertibles mostly steady, some vol. names up as equities slide; WellPoint flat; AMAG slips
|
| 4/1/2014 | CV | Market Commentary: Medicines expands on hedge after court opinion; McDermott nearly flat in gray market
|
| 3/20/2014 | CV | Market Commentary: Midday Commentary: new National Health Investors trades around par; Jarden 1.875% convert in trade
|
| 3/17/2014 | CV | Jarden greenshoe exercised, lifts 1.125% convertibles to $690 million
|
| 3/12/2014 | CV | Market Commentary: Midday Commentary: New Jarden seen flat to lower in aftermarket; Apollo at 101; Vipshop at 101.5
|
| 3/12/2014 | CV | New Issue: Jarden prices $600 million 20-year convertibles at 1.125%, up 22.5%
|
| 3/12/2014 | CV | Market Commentary: New Vipshop adds outright, unchanged on hedge; Carriage Services, ModusLink deals on tap
|
| 3/12/2014 | BKCVHYLM | Jarden raises capital, increases share repurchase amount, eyes year-end leverage target
|
| 3/11/2014 | BKCVHY | S&P rates Jarden convertibles BB-
|
| 3/11/2014 | CV | Market Commentary: Midday Commentary: Jarden's planned deal looks slightly rich; existing Jarden lower; Apollo on tap
|
| 3/11/2014 | CV | Jarden to price $600 million 20-year convertibles to yield 1%-1.25%, up 20%-25%
|
| 3/11/2014 | CV | Market Commentary: Planned Jarden near issue price in gray market; existing Jarden lower; Apollo REIT on tap
|
| 9/17/2013 | BKCVHYIG | S&P ups Jarden, loans & notes; rates loan BBB-
|
| 9/13/2013 | BKCVHY | Moody's gives Jarden loans Ba1
|
| 6/12/2013 | CV | Jarden greenshoe exercised, lifts convertible sale to $265.2 million
|
| 6/7/2013 | CV | New Issue: Jarden sells $250 million six-year convertibles to yield 1.5%, up 30%
|
| 6/7/2013 | CV | Market Commentary: Jarden trades modestly better; Exide tanks on bankruptcy chatter; Dominion little changed
|
| 6/6/2013 | CV | Market Commentary: Planned Jarden looks fair to rich; existing Jarden slips on swap; market seen quiet, weak
|
| 6/6/2013 | BKCVHY | Moody's ups Jarden notes, rates convertibles B1
|
| 6/6/2013 | BKCVHY | S&P: Jarden convertibles B
|
| 6/6/2013 | CV | Jarden plans to sell $250 million six-year convertible notes to yield 1%-1.5%, up 30%-35%
|
| 10/25/2012 | CV | Market Commentary: PSS World mostly breaks even on takeout news; Jarden trades down in line; AMD off lows
|
| 9/18/2012 | CV | Jarden greenshoe exercised, lifts convertible sale to $500 million
|
| 9/14/2012 | BKCVHY | Moody's: Jarden convertibles B2
|
| 9/13/2012 | CV | Market Commentary: Jarden performs well on debut; Meritage above par; Genesee & Wyoming mandatory on tap
|
| 9/12/2012 | BKCVHY | S&P: Jarden convertibles B
|
| 9/12/2012 | CV | New Issue: Jarden prices $450 million six-year convertibles at 1.875%, up 34%
|
| 9/12/2012 | CV | Market Commentary: New Sequenom pops on debut; Sanchez also lifts; Jarden revises talk, prices; Genesee to price
|
| 9/11/2012 | CV | Jarden plans to sell $450 million six-year convertibles to yield 1.875%, up 27.5%-32.5%
|
| 9/11/2012 | CV | Market Commentary: Planned Sequenom seen cheap; Jarden, Sanchez Energy launch; D.R. Horton trades in line
|
| 4/27/2009 | CVHY | Jarden files automatic shelf that includes equity, debt, guarantees
|
